Application of Viral Vectors for Vaccine Development
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: 1 May 2024 | Viewed by 2500
Special Issue Editor
Special Issue Information
Dear Colleagues,
In the quest to develop novel vaccines, DNA, mRNA, inactivated, live attenuated, virion-like particle, recombinant subunit and viral vector platforms have been employed. Both traditional and genetically engineered vaccines have contributed to the control of infectious disease pandemics, such as COVID-19. However, viral vectors, which can induce robust humoral and cellular immune responses, have attracted increased attention in recent years. Viral vector vaccines have been applied in both pre-clinical and clinical trials as vaccines against a variety of infectious diseases, such as HIV-1, Malaria, Ebola, and SARS-CoV-2, etc.
This Special Issue will provide a platform through which to discuss potential novel strategies and provision of enhanced vaccine designs, research works, and experimental results regarding the development of viral vector vaccines for both infectious and non-infectious diseases. We are pleased to invite you to contribute to this Special Issue with original research articles and reviews that focusing topics that include, but are not limited to, the following:
- Viral vector vaccine development and efficacy evaluation
- Vaccine technology
- Cancer vaccine
- Multiple vaccine technological platforms
- Protective mechanisms
- Immune response to vaccines
We eagerly anticipate receiving your contributions.
Prof. Dr. Fei Guo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- viral vector vaccines
- vaccine design
- immune response
- protection
